Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host a conference call to discuss topline data from the PACIFIC Study, a Phase 1b/2a clinical trial evaluating bexicaserin (LP352) in participants with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Bexicaserin is a potentially best-in-class, oral, novel, 5-HT2C receptor superagonist with no observed impact on 5-HT2B and 5-HT2A receptor subtypes.
Conference Call and Webcast Details
Longboard will host a conference call tomorrow, January 2, at 8:30am ET. Stockholders and other interested parties may participate in the call by following the instructions below. The live webcast can be accessed on the Events & Presentations portion of the investor page of Longboard’s website at https://ir.longboardpharma.com. A replay will be available on Longboard’s website shortly after completion of the event and will be archived for up to 30 days.
Participant Webcast Link: https://edge.media-server.com/mmc/p/sqg9yxpf
Participant Call Link: https://register.vevent.com/register/BIb92b4a3dd66f44fdbc3fcd202fca9caf
1. | Click on the call link and complete the online registration form. | |
2. | Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details. | |
3. | Select a method for joining the call; | |
| i. Dial-In: A dial in number and unique PIN are displayed to connect directly from your phone. | |
| ii. Call Me: Enter your phone number and click “Call Me” for an immediate callback from the system. The call will come from a U.S. number. https://www.businesswire.com/news/home/20240101532190/en/ |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.